Prostate Cancer Screening: a Pilot Study

Enrolling by invitation · Not applicable

Conditions studied: Prostate Cancer

In brief

Prostate Cancer (PCa) is the second most frequently diagnosed tumour and the third most lethal among men in Europe. The lack of precise tools and examinations to precisely diagnose PCa has caused overtreatment of indolent and low-aggressive PCa, while in some other cases, with aggressive disease, diagnosis and treatment are dangerously delayed because cancer could be potentially missed. The present trial aims to study a new pathway to early diagnose PCa with Magnetic Resonance Imaging (MRI) to identify men who will not need treatment and those who will benefit from radical treatment, thus improving disease control and quality of life.

Key facts

Study ID

NCT06238661

Run by

Fondazione del Piemonte per l'Oncologia

People needed

4500

Starts

2025-02-17

Expected to finish

2026-06-30

Last updated by the study team

2026-03-05

Who can join

Age: 55 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• age between 55-65 years;
• asymptomatic or paucisymptomatic from a urological point of view;
• no previous prostate biopsy;
• living in the ASL TO5 (Piedmont, Italy);
• signed written informed consent.

You may not qualify if…

• positive oncologic anamnesis for prostate cancer;
• previous biopsy or prostate surgery;
• previous radiotherapy of the pelvis;
• any contraindication to MRI examination;
• claustrophobic or uncollaborative subjects.

Where it is running

• Fondazione del Piemonte per l'Oncologia — Candiolo, Italy, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.